---
title: "Aquestive Therapeutics, Inc. (AQST.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AQST.US.md"
symbol: "AQST.US"
name: "Aquestive Therapeutics, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-19T20:26:35.253Z"
locales:
  - [en](https://longbridge.com/en/quote/AQST.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AQST.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AQST.US.md)
---

# Aquestive Therapeutics, Inc. (AQST.US)

## Company Overview

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron;  SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company’s proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.aquestive.com](https://www.aquestive.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: C (0.60)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 77 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -7.30% |  |
| Net Profit YoY | -27.05% |  |
| P/B Ratio | -15.23 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 518736242.07 |  |
| Revenue | 50271000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 145.10% | A |
| Profit Margin | -137.08% | E |
| Gross Margin | 75.99% | A |
| Revenue YoY | -7.30% | D |
| Net Profit YoY | -27.05% | D |
| Total Assets YoY | 38.04% | A |
| Net Assets YoY | 44.11% | A |
| Cash Flow Margin | 63.62% | C |
| OCF YoY | -7.30% | D |
| Turnover | 0.41 | C |
| Gearing Ratio | 124.13% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Aquestive Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-7.30%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-27.05%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-15.23",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "518736242.07",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "50271000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "145.10%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-137.08%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "75.99%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-7.30%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-27.05%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "38.04%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "44.11%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "63.62%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-7.30%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.41",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "124.13%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -7.53 | 176/190 | - | - | - |
| PB | -15.23 | 226/190 | - | - | - |
| PS (TTM) | 10.32 | 116/190 | 16.45 | 11.32 | 7.38 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 78% |
| Overweight | 2 | 22% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.09 |
| Highest Target | 11.00 |
| Lowest Target | 6.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AQST.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AQST.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AQST.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AQST.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**